TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2025573

Group type: EXPERIMENTAL
Intervention: Daunorubicin, cytosine arabinoside and thioguanine combination
Number of subjects: 156

Group type: COMPARATOR
Intervention: Lower dosages of daunorubicin, cytosine arabinoside, etoposide and vindesine
Number of subjects: 156
Study: 7249899

Group type: EXPERIMENTAL
Intervention: 1.6 mm needle
Number of subjects: 97

Group type: COMPARATOR
Intervention: 1.9 mm needle
Number of subjects: 97
Study: 6543133

Group type: EXPERIMENTAL
Intervention: Ferric(III)‐dextrin complex
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fe(II)‐sulfate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fe(II)‐fumarate with vitamins
Number of subjects: 60
Study: 30199128

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Supportive therapy (SP)
Number of subjects: 268
Study: 26136435

Group type: EXPERIMENTAL
Intervention: Orofacial Myofunctional Therapy (OMT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-OMT (Control)
Number of subjects: 22
Study: 24885811

Group type: EXPERIMENTAL
Intervention: Usual care plus additional rehabilitation service on Saturday
Number of subjects: 996

Group type: COMPARATOR
Intervention: Usual care rehabilitation services from Monday to Friday
Number of subjects: 996
Study: 22914255

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich olive oil (∼30 mg/day)
Number of subjects: 24
Study: 20360461

Group type: EXPERIMENTAL
Intervention: Augmented communication input (AC-I)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Augmented communication output (AC-O)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Spoken communication (SC)
Number of subjects: 68
Study: 18561116

Group type: EXPERIMENTAL
Intervention: Neuromonics Tinnitus Treatment (customized neural stimulus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noise+Counseling (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counseling-Only (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuromonics Tinnitus Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noise+Counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counseling-Only
Number of subjects: 0
Study: 15809910

Group type: EXPERIMENTAL
Intervention: ORS with L-histidine (2.5 g/L)
Number of subjects: 126

Group type: COMPARATOR
Intervention: ORS without L-histidine
Number of subjects: 126
Study: 12398233

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (Ortho Tri-Cyclen: norgestimate and ethinylestradiol)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 10605165

Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy (206.4 ± 44.4 mg/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Lamotrigine combined with carbamazepine (1208 ± 82.9 mg/day + 561.7 ± 76.8 mg/day)
Number of subjects: 47
Study: 7489420

Group type: EXPERIMENTAL
Intervention: Oxygen (FiO2 1.0)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: N2O/O2 (FiO2 0.4)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Air/O2 (FiO2 0.4)
Number of subjects: 25
Study: 1659440

Group type: EXPERIMENTAL
Intervention: 1 mg ml‐1 443C81
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 4 mg ml‐1 443C81
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 9
Study: 7037414

Group type: EXPERIMENTAL
Intervention: Oxprenolol 40 mg b.d.
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 30273200

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose IT naloxone (20 μg) and IT morphine (0.2 mg)
Number of subjects: 77

Group type: COMPARATOR
Intervention: IT morphine (0.2 mg) alone
Number of subjects: 77
Study: 31003657

Group type: EXPERIMENTAL
Intervention: Active video game intervention (twice a week for 45 minutes over eight weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 15
Study: 27663611

Group type: COMPARATOR
Intervention: Online first group (invited to complete the questionnaire online)
Number of subjects: 8795

Group type: EXPERIMENTAL
Intervention: Choice group (sent a paper questionnaire and offered a choice of completion method)
Number of subjects: 8795
Study: 25542616

Group type: EXPERIMENTAL
Intervention: Eyelid hygiene with neutral shampoo three times/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Neutral shampoo eyelid hygiene plus topical metronidazole gel 0.75% twice/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Neutral eyelid hygiene with shampoo plus neomycin 3.5% and polymyxin 10% antibiotic ointment with 0.5% dexamethasone 3 times/day
Number of subjects: 45
Study: 23497438

Group type: EXPERIMENTAL
Intervention: Implementation activities by facilitators
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Robust evidence base
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Alignment of processes with existing initiatives
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Implementation context challenges
Number of subjects: 151
Study: 21357957

Group type: EXPERIMENTAL
Intervention: Bilateral simultaneous total knee replacement (TKR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Unilateral total knee replacement (TKR)
Number of subjects: 150
Study: 18288078

Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg p.o.)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg p.o.)
Number of subjects: 13
Study: 17063175

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (age- and gender-matched healthy controls)
Number of subjects: 0
Study: 12757769

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAC) with a target INR of 2.0-2.5 and aspirin 75 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study: 11530046

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 48
Study: 9432455

Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-help group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 0
Study: 8235133

Group type: EXPERIMENTAL
Intervention: Social support and health education intervention, including four to six visits during pregnancy, telephone hotline, consultation service, and health education materials.
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 620
Study: 3613407

Group type: EXPERIMENTAL
Intervention: Heparin free hemodialysis
Number of subjects: 29

Group type: COMPARATOR
Intervention: Systemic heparinization, intermittent saline flushes, and constant saline infusions
Number of subjects: 29
Study: 30368509

Group type: EXPERIMENTAL
Intervention: Daily treatment with S-1
Number of subjects: 75

Group type: COMPARATOR
Intervention: Alternate-day treatment with S-1
Number of subjects: 75
Study: 26189608

Group type: EXPERIMENTAL
Intervention: Coffee ingestion and repeated bouts of low-intensity exercise (CR)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Coffee ingestion and single bout of low-intensity exercise (CS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Repeated bouts of low-intensity exercise with plain hot water (WR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Single bout of low-intensity exercise with plain hot water (WS)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Repeated bouts of low-intensity exercise with coffee (CR)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Single bout of low-intensity exercise with coffee (CS)
Number of subjects: 7
Study: 26160892

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Urine monitoring
Number of subjects: 18
Study: 22918663

Group type: EXPERIMENTAL
Intervention: Full mouth non‐surgical periodontal therapy followed by open flap surgery
Number of subjects: 12
Study: 21239119

Group type: EXPERIMENTAL
Intervention: MDD+ smokers
Number of subjects: 101

Group type: COMPARATOR
Intervention: MDD- smokers
Number of subjects: 101
Study: 18474764

Group type: EXPERIMENTAL
Intervention: Blacks
Number of subjects: 333
Study: 16114063

Group type: EXPERIMENTAL
Intervention: Clover phytoestrogens 240 mg daily for 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14526951

Group type: EXPERIMENTAL
Intervention: Urinary excretion rates measured in microg U g(‐1) creatinine for 1997 and 1999.
Number of subjects: 33
Study: 10971313

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (loading dosage and constant infusion)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral lovastatin (20 mg)
Number of subjects: 10
Study: 8617086

Group type: EXPERIMENTAL
Intervention: PGI2 (Prostacyclin) at a dose of 2 to 12 ng/kg/min, IV, infused continuously for 48 h
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1548451

Group type: EXPERIMENTAL
Intervention: Caffeine 178 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caffeine doses (100 mg, 56 mg, 32 mg, 18 mg, 10 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2984846

Group type: EXPERIMENTAL
Intervention: 500 micrograms anti-Rh intramuscularly
Number of subjects: 14

Group type: COMPARATOR
Intervention: 0.28 ml of Rh-positive red cells (challenge)
Number of subjects: 14
Study: 31553222

Group type: EXPERIMENTAL
Intervention: Absorb everolimus-eluting bioresorbable vascular scaffold (BVS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cobalt chromium everolimus-eluting stents (EES)
Number of subjects: 0
Study: 28901839

Group type: EXPERIMENTAL
Intervention: Group-based educational training based on the PRECEDE-PROCEED model
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 27505205

Group type: EXPERIMENTAL
Intervention: Images of negative health outcomes
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Images of positive health outcomes
Number of subjects: 711

Group type: COMPARATOR
Intervention: No image control
Number of subjects: 711
Study: 25033105

Group type: EXPERIMENTAL
Intervention: BuMA (PLGA-polymer with electro-grafting base layer sirolimus-eluting stent)
Number of subjects: 80

Group type: COMPARATOR
Intervention: EXCEL (PLA-polymer sirolimus-eluting stent)
Number of subjects: 80
Study: 23141144

Group type: EXPERIMENTAL
Intervention: Clobazam at dosages ≤2.0 mg/kg/day (≤80 mg/day)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Clobazam for ≥12 months
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Clobazam for ≥1 year
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 267
Study: 20979934

Group type: EXPERIMENTAL
Intervention: Probenecid (PRB) co-administered with Mizoribine (MZR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mizoribine (MZR) alone
Number of subjects: 12
Study: 18981007

Group type: EXPERIMENTAL
Intervention: CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) for three cycles followed by 90Y-ibritumomab tiuxetan (RIT) and extended rituximab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CHOP-R followed by RIT
Number of subjects: 60
Study: 15864879

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg once daily
Number of subjects: 249

Group type: COMPARATOR
Intervention: Cetirizine 10 mg
Number of subjects: 249
Study: 12798283

Group type: EXPERIMENTAL
Intervention: Glucose 100 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose 500 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose 50 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (23.7 mg saccharin)
Number of subjects: 0
Study: 10482985

Group type: EXPERIMENTAL
Intervention: Axl expression present (19 out of 54 cases, 35%)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Axl expression absent (not specified how many cases)
Number of subjects: 54
Study: 8961362

Group type: EXPERIMENTAL
Intervention: 44 Gy in 16 daily fractions of radiation therapy (RT)
Number of subjects: 186
Study: 8144848

Group type: EXPERIMENTAL
Intervention: GH treatment alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Clinical follow‐up (group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GH + LHRHa treatment
Number of subjects: 18
Study: 3529772

Group type: EXPERIMENTAL
Intervention: 5000 IU of heparin + 0.5 mg dihydroergotamine (HDHE) s.c. every 12 hours
Number of subjects: 86

Group type: COMPARATOR
Intervention: 5000 IU of heparin (LDH) s.c. every 8 hours
Number of subjects: 86
Study: 28700428

Group type: EXPERIMENTAL
Intervention: Collection of lymph nodes (LNs) into nodal basin-specific containers
Number of subjects: 56

Group type: COMPARATOR
Intervention: Simple labeling of lymph nodes on the nonrandomized side
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Processing of additional adipose tissue
Number of subjects: 56
Study: 27362270

Group type: EXPERIMENTAL
Intervention: Early medical abortion provided by nurse-midwives
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Standard procedure (early medical abortion provided by physicians)
Number of subjects: 1180
Study: 24622114

Group type: EXPERIMENTAL
Intervention: Physical examination finding: Peripheral edema
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Physical examination finding: Pulmonary rales
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Physical examination finding: Jugular venous distension
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Physical examination finding: Third heart sound
Number of subjects: 1376
Study: 22331336

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 51
Study: 20683456

Group type: EXPERIMENTAL
Intervention: 30g fibre of potatoes (FP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 30g wrinkle pea starch (WPS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 375g Lactobacillus acidophilus (LC1) yoghurt
Number of subjects: 14
Study: 19167589

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg QD
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg QD
Number of subjects: 339
Study: 15938887

Group type: EXPERIMENTAL
Intervention: Modified base-type pontics
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified ridge lap pontics
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ovata pontics
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Before tooth preparation and 3 months after fixed prosthesis insertion
Number of subjects: 60
Study: 15320851

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination ARB/ACE inhibitor therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitor therapy alone
Number of subjects: 0
Study: 9477387

Group type: EXPERIMENTAL
Intervention: Nutritional formula (NF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard test meal (ST)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glucose test meal (GT)
Number of subjects: 12
Study: 8029088

Group type: EXPERIMENTAL
Intervention: Buserelin, 1800 micrograms/day as nasal spray
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triptorelin Depot, 3.75 mg/every 4 weeks i.m.
Number of subjects: 12
Study: 2567345

Group type: COMPARATOR
Intervention: SKF 39393 (selective D-1 dopamine receptor agonist) at daily doses ranging from 3.2 to 32 mg/kg over treatment intervals of one to seven weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 1153447

Group type: EXPERIMENTAL
Intervention: Ethanol self-administration (8 drinks of ethanol, 89.12 g total)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Orange juice self-administration (8 drinks of orange juice)
Number of subjects: 4
Study: 30629160

Group type: EXPERIMENTAL
Intervention: Targeted therapy including mineralocorticoid receptor antagonists, statins, ACE inhibitors and/or receptor blockers, and cardiac rehabilitation.
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 230

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 230
Study: 29066163

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 26173635

Group type: EXPERIMENTAL
Intervention: CRT-D in patients with LVEF ≤30% (n = 1100)
Number of subjects: 1783

Group type: EXPERIMENTAL
Intervention: CRT-D in patients with LVEF >30% (n = 683)
Number of subjects: 1783

Group type: EXPERIMENTAL
Intervention: Each 5% increment in LVEF
Number of subjects: 1783

Group type: EXPERIMENTAL
Intervention: CRT-D treatment effect by LVEF interaction
Number of subjects: 1783
Study: 23215626

Group type: EXPERIMENTAL
Intervention: Focused ultrasound stimulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 50
Study: 21520154

Group type: EXPERIMENTAL
Intervention: Combination of biomarkers PSMA, PSGR, and PCA3 detected by quantitative real-time PCR in post-PM urine sediment.
Number of subjects: 154
Study: 18316236

Group type: EXPERIMENTAL
Intervention: Stuttering patients with abnormal movements (AMs)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Involuntary movements concurrent to speech
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Involuntary movements not concurrent to speech
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Conscious control of movement during speech
Number of subjects: 85
Study: 16569543

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 537
Study: 12764406

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (20 mg/day)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/day)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 10684842

Group type: EXPERIMENTAL
Intervention: Vancomycin eye drops applied to the medial canthus with closed lids
Number of subjects: 53

Group type: COMPARATOR
Intervention: Vancomycin eye drops applied to the lower cul de sac with open lids (conventional method)
Number of subjects: 53
Study: 9444445

Group type: EXPERIMENTAL
Intervention: Interferon alfa (480 million U over 6 months)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No drug treatment (Control)
Number of subjects: 82
Study: 8127929

Group type: EXPERIMENTAL
Intervention: Moclobemide (300‐600 mg/d)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Maprotiline (75‐150 mg/d)
Number of subjects: 115
Study: 3426682

Group type: EXPERIMENTAL
Intervention: Calcium carbimide (50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28985255

Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg orally twice-daily (maximum of 14 doses)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 27177609

Group type: EXPERIMENTAL
Intervention: Tailored assistive technology intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 240
Study: 26283079

Group type: EXPERIMENTAL
Intervention: Reduced restriction protocol (no recommendations regarding sleeping position)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Care as usual (postoperative restrictions including advice to sleep in a supine position for the first 8 weeks)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Reduced restriction protocol
Number of subjects: 456
Study: 23510450

Group type: EXPERIMENTAL
Intervention: 17 G/ 35 mm (standard) needle
Number of subjects: 21

Group type: COMPARATOR
Intervention: 20 G/ 35 mm (thin) needle
Number of subjects: 21
Study: 20883866

Group type: EXPERIMENTAL
Intervention: EUS-guided ethanol lavage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Follow-up CT
Number of subjects: 12
Study: 18602599

Group type: EXPERIMENTAL
Intervention: Targeted therapy (specific molecules not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytotoxic chemotherapy (not explicitly detailed)
Number of subjects: 0
Study: 16736333

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (intravenous for 2 days, followed by oral for 10 days)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Surgery (open or laparoscopic appendectomy)
Number of subjects: 252
Study: 12803270

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 11775892

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg-20 mg, three times daily before labor, orally every 6 hours during labor)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no Nifedipine during labor)
Number of subjects: 64
Study: 8649570

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Topiramate 400 mg/day
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Topiramate 600 mg/day
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 1517944

Group type: EXPERIMENTAL
Intervention: Diosmectite
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 7036292

Group type: EXPERIMENTAL
Intervention: Chemotherapy with 5-fluorouracil (10 mg/kg/day) and BCNU (40 mg/m2/day) for 5 days, administered eight times in 6‐8 week intervals.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no chemotherapy).
Number of subjects: 103
Study: 30239491

Group type: EXPERIMENTAL
Intervention: 30-min nap after a reference night
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 30-min nap after a partial sleep deprivation night
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 30-min nap after fatigue induced by KST
Number of subjects: 13
Study: 29705869

Group type: EXPERIMENTAL
Intervention: Suvorexant 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Suvorexant 40 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Suvorexant 80 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Suvorexant 100 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Suvorexant (all doses)
Number of subjects: 40